| Description | Molnupiravir (MK-4482) (EIDD-2801) is a prodrug of the ribonucleoside analog EIDD-1931 which is orally bioavailable. Molnupiravir can be used in COVID-19, seasonal and pandemic influenza research that has broad spectrum antiviral activity against multiple coronaviruses and influenza virus, for example, SARS-CoV-2, MERS-CoV, SARS-CoV [1][2]. |
| In vitro | Molnupiravir（50-500 mg/kg；口服；每12小时一次，连续3天）具有强大的抗病毒活性，能够阻止SARS-CoV的复制和疾病发展[1]。此外，Molnupiravir（7 mg/kg；口服；一天两次，持续3.5天）显著降低了病毒排放量和发热持续时间[2]。 |
| Synonyms | EIDD-2801, Lagevrio, MK-4482 |
| molecular weight | 329.31 |
| Molecular formula | C13H19N3O7 |
| CAS | 2492423-29-5 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 40 mg/mL (121.47 mM), Sonication is recommended. |
| References | 1. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. 2. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866. |